Xconomy -- Vancouver, BC-based Indel Therapeutics, the developer of new antibiotics, is announcing today it has raised $1.4 million in a second round of financing. Morningside Ventures, MAD Ventures, and Quantum Pacific Capital participated in the deal. I last profiled Indel two years ago, as CEO Malcolm Kendall outlined the company’s strategy for pursuing novel biological targets, and creating antibiotics that fight tough-to-treat hospital based infections.
